- Home
- CRVS vs OPRT Comparison
CRVS vs OPRT Comparison
Compare CRVS & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- OPRT
- Stock Information
- Founded
- CRVS 2014
- OPRT 2005
- Country
- CRVS United States
- OPRT United States
- Employees
- CRVS N/A
- OPRT N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- OPRT Finance: Consumer Services
- Sector
- CRVS Health Care
- OPRT Finance
- Exchange
- CRVS Nasdaq
- OPRT Nasdaq
- Market Cap
- CRVS 305.4M
- OPRT 264.1M
- IPO Year
- CRVS 2016
- OPRT 2019
- Fundamental
- Price
- CRVS $5.75
- OPRT $6.61
- Analyst Decision
- CRVS Strong Buy
- OPRT Hold
- Analyst Count
- CRVS 4
- OPRT 2
- Target Price
- CRVS $15.00
- OPRT $8.00
- AVG Volume (30 Days)
- CRVS 494.0K
- OPRT 594.9K
- Earning Date
- CRVS 08-07-2025
- OPRT 08-06-2025
- Dividend Yield
- CRVS N/A
- OPRT N/A
- EPS Growth
- CRVS N/A
- OPRT N/A
- EPS
- CRVS N/A
- OPRT N/A
- Revenue
- CRVS N/A
- OPRT $724,757,000.00
- Revenue This Year
- CRVS N/A
- OPRT $27.48
- Revenue Next Year
- CRVS N/A
- OPRT $5.29
- P/E Ratio
- CRVS N/A
- OPRT N/A
- Revenue Growth
- CRVS N/A
- OPRT N/A
- 52 Week Low
- CRVS $2.54
- OPRT $2.37
- 52 Week High
- CRVS $10.00
- OPRT $9.25
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- OPRT 58.35
- Support Level
- CRVS $5.28
- OPRT $5.51
- Resistance Level
- CRVS $5.64
- OPRT $6.67
- Average True Range (ATR)
- CRVS 0.30
- OPRT 0.28
- MACD
- CRVS 0.03
- OPRT 0.10
- Stochastic Oscillator
- CRVS 77.70
- OPRT 90.50
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.